Journal
BRITISH JOURNAL OF CANCER
Volume 100, Issue 1, Pages 13-18Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604822
Keywords
hormone refractory prostate cancer; xenografts; novel therapeutics; PSA biomarker
Categories
Ask authors/readers for more resources
With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available